Butensky & Cohen Financial Security’s AstraZeneca AZN Stock Holding History

Butensky & Cohen Financial Security’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-106	Closed	-$7K	–	132
2015 Q4	$7K	Buy	106 +6	+6%	+$393	0.01%	109
2015 Q3	$6K	Buy	+100	New	+$6.58K	0.01%	109

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Butensky & Cohen Financial Security's AZN Position: Q1 2016 in Review

Butensky & Cohen Financial Security sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 106 shares — an estimated $7K sold.

Butensky & Cohen Financial Security first reported a position in AZN in Q3 2015 and held it in 2 quarters. The position peaked at $7K in Q4 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

Butensky & Cohen Financial Security reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
Butensky & Cohen Financial Security sold 106 AstraZeneca shares in Q1 2016, an estimated $7K.
Butensky & Cohen Financial Security first reported a position in AstraZeneca in Q3 2015 and held it in 2 quarters.
Butensky & Cohen Financial Security's AstraZeneca position peaked at $7K in Q4 2015.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Butensky & Cohen Financial Security's 13F filing for Q1 2016, filed 19 Apr 2016.